Watch out, As­traZeneca: UCB un­corks late-stage suc­cess for $2.1B Soliris ri­val

Just over two years af­ter spend­ing more than $2 bil­lion to ac­quire the drug, UCB an­nounced that zilu­coplan proved ef­fec­tive at treat­ing the rare au­toim­mune dis­ease myas­the­nia gravis in a large Phase III tri­al.

Al­though UCB de­clined to share any spe­cif­ic num­bers, the Bel­gian phar­ma said pa­tients on the drug showed sig­nif­i­cant im­prove­ment over place­bo on all pri­ma­ry and sec­ondary end­points, no­tably in­clud­ing three dif­fer­ent scales used to track symp­toms of the com­plex dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER